Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Bob Swift who wrote (1874)	3/2/1999 6:24:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 10280

Bob, None of the drugs SEPR is developing have as their only advantage a smaller dose (your case III). They all have one or more of: reduced side effects, quicker onset of action, fewer drug interactions or better efficacy. Thus Xopenex is confirmed to have reduced immediate side effects, and may also have an important advantage for long-term use. If the latter is confirmed it will totally dominate the market; if not it will still take a big share of it. Peter

To: Bob Swift who wrote (1874)	3/2/1999 9:34:00 PM
From: David Howe	Read Replies (1) \| Respond to of 10280

Bob, Point well taken. My response was too simplistic. I forgot who I was talking to (which comes from reading the Yahoo board where 1/2 the participants are still trying to figure out the stock symbol). You've obviously given this more thought than I have, and the subject is worthy of further discussion. Here's a list of the ICEs that are furthest along. Perhaps someone could take a stab at what group each of these falls into. My first pass brought me to the conclusion that most fall into group 2 (one isomer is good and both isomers have some side effects). Am I correct that it will be very rare to find a scenario such as the following: > One isomer has the desired therapeutic effect and no side effects at all. > One isomer has the desired therapeutic effect and also carries 100% of the side effects. My guess is that most of the ICEs will have the therapeutic effect and will have some but less side effects (ie. decreased in occurrence, decreased in severity, decreased in type or quantity). In this case, it really will come down to marketing as Peter has pointed out. Any thoughts? Fexofenadine (Allegra) Xopenex (Levalbuteral) Norastemizole (Hismanal ICE) DCL (Claritin ICE) (S)-Oxybutynin (Ditropan ICE) (R,R)-Formoterol (Foradil ICE) (S)-doxazosin (Cardura ICE) (R)-fluoxetine (Prozac ICE)